Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data

The Lancet Oncology

Volumn 18, Issue 1, 2017, Pages 132-142

  Guinney, Justin ^a   Wang, Tao ^b   Laajala, Teemu D ^d,e   Winner, Kimberly Kanigel ^g   Bare, J Christopher ^a   Neto, Elias Chaibub ^a   Khan, Suleiman A ^e   Peddinti, Gopal ^e   Airola, Antti ^d   Pahikkala, Tapio ^d   Mirtti, Tuomas ^e,f   Yu, Thomas ^a   Bot, Brian M ^a   Shen, Liji ^p   Abdallah, Kald ⁱ   Norman, Thea ^a   Friend, Stephen ^a   Stolovitzky, Gustavo ^j   Soule, Howard ^k   Sweeney, Christopher J ^l   Ryan, Charles J ^m   Scher, Howard I ⁿ   Sartor, Oliver ^o   Xie, Yang ^b,c   Aittokallio, Tero ^d,e   Zhou, Fang Liz ^p   Costello, James C ^g,h   more..

^a SAGE BIONETWORKS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TURKU   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF COLORADO CANCER CENTER   (United States)

ⁱ ASTRAZENECA   (United Kingdom)

^j IBM T J WATSON RESEARCH CENTER   (United States)

^k Prostate Cancer Foundation   (United States)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p SANOFI   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ASPARTATE AMINOTRANSFERASE; CREATININE; DOCETAXEL; LACTATE DEHYDROGENASE; LENALIDOMIDE; PLACEBO; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ZIBOTENTAN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE COUNT; HIGH RISK POPULATION; HUMAN; INTEGRATED AREA UNDER CURVE; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; BAYES THEOREM; CANCER STAGING; CLINICAL TRIAL; CROWDSOURCING; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NOMOGRAM; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; STATISTICAL MODEL; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; CROWDSOURCING; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; NOMOGRAMS; PREDNISONE; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TAXOIDS; YOUNG ADULT;

EID: 85006765760     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30560-5     Document Type: Article

References (34)

1. 1 Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E, Forman, D, Global cancer statistics. CA Cancer J Clin 61 (2011), 69–90.
2. 2 Tanimoto, T, Hori, A, Kami, M, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363, 2010, 1966.
3. 3 Berruti, A, Pia, A, Terzolo, M, Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 365, 2011, 766.
4. 4 Fizazi, K, Carducci, M, Smith, M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377 (2011), 813–822.
5. 5 Ryan, CJ, Smith, MR, de Bono, JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 (2013), 138–148.
6. 6 Scher, HI, Fizazi, K, Saad, F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
7. 7 de Bono, JS, Oudard, S, Ozguroglu, M, et al., for the TROPIC investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 (2010), 1147–1154.
8. 8 Parker, C, Nilsson, S, Heinrich, D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369 (2013), 213–223.
9. 9 Kantoff, PW, Higano, CS, Shore, ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363 (2010), 411–422.
10. 10 Beer, TM, Armstrong, AJ, Rathkopf, DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 (2014), 424–433.
11. 11 Halabi, S, Small, EJ, Kantoff, PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003), 1232–1237.
12. 12 Smaletz, O, Scher, HI, Small, EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20 (2002), 3972–3982.
13. 13 Armstrong, AJ, Garrett-Mayer, ES, Yang, Y-CO, de Wit, R, Tannock, IF, Eisenberger, M, A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13 (2007), 6396–6403.
14. 14 Halabi, S, Lin, C-Y, Kelly, WK, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 32 (2014), 671–677.
15. 15 Okser, S, Pahikkala, T, Airola, A, Salakoski, T, Ripatti, S, Aittokallio, T, Regularized machine learning in the genetic prediction of complex traits. PLoS Genet, 10, 2014, e1004754.
16. 16 Papaemmanuil, E, Gerstung, M, Bullinger, L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374 (2016), 2209–2221.
17. 17 Longo, DL, Drazen, JM, Data sharing. N Engl J Med 374 (2016), 276–277.
18. 18 Scher, HI, Jia, X, Chi, K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 29 (2011), 2191–2198.
19. 19 Petrylak, DP, Vogelzang, NJ, Budnik, N, et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 16 (2015), 417–425.
20. 20 Tannock, IF, Fizazi, K, Ivanov, S, et al., on behalf of the VENICE investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 14 (2013), 760–768.
21. 21 Fizazi, K, Fizazi, KS, Higano, CS, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 31 (2013), 1740–1747.
22. 22 Nelson, JB, Fizazi, K, Miller, K, et al. Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). Proc Am Soc Clin Oncol, 29, 2011 abstr 117.
23. 23 Hung, H, Chiang, C-T, Estimation methods for time-dependent AUC models with survival data. Can J Stat 38 (2010), 8–26.
24. 24 Project Data Sphere. Prostate cancer DREAM challenge. https://www.projectdatasphere.org/projectdatasphere/html/pcdc (accessed Oct 21, 2016).
25. 25 Costello, JC, Stolovitzky, G, Seeking the wisdom of crowds through challenge-based competitions in biomedical research. Clin Pharmacol Ther 93 (2013), 396–398.
26. 26 Bender, E, Challenges: crowdsourced solutions. Nature 533 (2016), S62–S64.
27. 27 Bansal, M, Yang, J, Karan, C, et al. A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol 32 (2014), 1213–1222.
28. 28 Costello, JC, Heiser, LM, Georgii, E, et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol 32 (2014), 1202–1212.
29. 29 Margolin, AA, Bilal, E, Huang, E, et al. Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med, 5, 2013, 181re1.
30. 30 Ewing, AD, Houlahan, KE, Hu, Y, et al. Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. Nat Methods 12 (2015), 623–630.
31. 31 Saez-Rodriguez, J, Costello, JC, Friend, SH, et al. Crowdsourcing biomedical research: leveraging communities as innovation engines. Nat Rev Genet 17 (2016), 470–486.
32. 32 Merson, L, Gaye, O, Guerin, PJ, Avoiding data dumpsters: toward equitable and useful data sharing. N Engl J Med 374 (2016), 2414–2415.
33. 33 Bierer, BE, Li, R, Barnes, M, Sim, I, A global, neutral platform for sharing trial data. N Engl J Med 374 (2016), 2411–2413.
34. 34 Lewis, B, Sartor, O, The changing landscape of metastatic prostate cancer. Am J Hematol 11 (2015), 11–20.